Sarepta Therapeutics, Inc. provided revenue guidance for the full year of 2022. The company raised full year total revenue guidance to between $905 million and $920 million and net product revenue guidance to between $825 million and $840 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.1 USD | -1.31% | -2.67% | +33.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.90% | 12.37B | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
-28.60% | 8.28B | |
+17.28% | 8.26B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022